Read by QxMD icon Read

IgA Nephropathy

shared collection
34 papers 25 to 100 followers
By P O Pediatrics, Nephrology
Alexandra Cambier, Olivia Boyer, Georges Deschenes, James Gleeson, Anne Couderc, Julien Hogan, Thomas Robert
IgA nephropathy (IgAN) is one the most common primary glomerulonephritis in children and adolescents worldwide, with 20% of children developing end-stage kidney disease (ESKD) within 20 years of diagnosis. There is a need for treatment guidelines, especially for steroids in children with primary IgAN, since the STOP-IgA trial casts doubts on the use of steroids in adults with intermediate risk. Pediatricians are prone to prescribe steroids in addition to renin-angiotensin system blockade (RASB) when proteinuria is > 0...
February 18, 2019: Pediatric Nephrology: Journal of the International Pediatric Nephrology Association
Mineaki Kitamura, Yoko Obata, Yuki Ota, Kumiko Muta, Hiroshi Yamashita, Takashi Harada, Hiroshi Mukae, Tomoya Nishino
Subepithelial deposits are observed in rare adult IgA nephropathy (IgAN) cases and are a key diagnostic finding in IgA-dominant infection-related glomerulonephritis (IgA-IRGN). Sometimes, it is difficult to distinguish IgA-IRGN from IgAN without a precise clinical history. We hypothesized that some IgA-IRGN cases might be diagnosed as IgAN with subepithelial deposits (IgAN-SD) and aimed to clarify the significance of subepithelial deposits in patients diagnosed with IgAN. We examined 464 patients diagnosed with IgAN at Nagasaki University Hospital and affiliated hospitals between 1996 and 2013...
2019: PloS One
Nicolas Maillard, Christophe Mariat
No abstract text is available yet for this article.
February 18, 2019: Nephrology, Dialysis, Transplantation
Tadasu Kojima, Go Hirose, Shuuhei Komatsu, Taito Oshima, Kentaro Sugisaki, Tomohiro Tomiyasu, Noriko Yoshikawa, Muneharu Yamada, Takashi Oda
BACKGROUND: Anti-glomerular basement membrane (GBM) glomerulonephritis does not usually coexist with another glomerulonephritis such as IgA nephropathy. We present a rare case having a combination of these two diseases, and furthermore, histological evaluation could be performed before and after the development of anti-GBM glomerulonephritis over a period of only10 months. CASE PRESENTATION: A 66-year-old woman was admitted with complaints of microscopic hematuria and mild proteinuria for the past 3 years...
January 25, 2019: BMC Nephrology
Judith Isabel Schimpf, Till Klein, Christina Fitzner, Frank Eitner, Stefan Porubsky, Ralf-Dieter Hilgers, Jürgen Floege, Hermann-Josef Groene, Thomas Rauen
BACKGROUND: The Oxford classification of IgA nephropathy (IgAN) defines histologic criteria (MEST-C) that provide prognostic information based on the kidney biopsy. There are few data on the predictive impact of this classification in randomized clinical trial settings. METHODS: We performed an exploratory analysis of MEST-C scores in 70 available renal biopsies from 162 randomized STOP-IgAN trial participants and correlated the results with clinical outcomes. Analyses were performed by researchers blinded to the clinical outcome of the patients...
November 19, 2018: BMC Nephrology
F Locatelli, L Del Vecchio, C Ponticelli
IgA nephropathy (IgAN) is the most common primary glomerulonephritis all over the world. Once considered as a benign disease, today the scientific community is aware that a significant percentage of patients eventually progress to end-stage kidney disease (ESKD). The rate of progression is often very slow. Since 1980s, several therapeutic attempts have been made with steroids. Despite different molecules, doses, and lengths of treatment, the majority of uncontrolled and controlled studies found benefits in terms of proteinuria reduction and reduction of the risk of ESKD...
June 1, 2018: Physiology International
Rosanna Coppo
Background: IgA nephropathy (IgAN) is detected in Europe in 22% of glomerular diseases diagnosed by biopsy. The frequency of IgAN as cause of ESRD in Europe has increased in the last decades, accounting for 35% of young and adult transplanted patients. These data justify the interest for risk factors and a possible therapeutic approach. Summary: Insight into a European perspective of IgAN was allowed by the multicenter study VALIGA, on 1,147 patients, almost all Caucasians, with follow-up of 4...
June 2018: Kidney Diseases
Jennifer C Rodrigues, Mark Haas, Heather N Reich
IgA nephropathy (IgAN) is a leading cause of CKD and renal failure. Recent international collaborative efforts have led to important discoveries that have improved our understanding of some of the key steps involved in the immunopathogenesis of IgAN. Furthermore, establishment of multicenter networks has contributed to rigorous design and execution of clinical trials that have provided important insights regarding immunotherapy in IgAN. In this article, we review emerging developments in clinical and translational IgAN research and describe how these novel findings will influence future strategies to improve the outcome of patients with IgAN...
April 3, 2017: Clinical Journal of the American Society of Nephrology: CJASN
Wei Peng, Yi Tang, Zheng Jiang, Zi Li, Xuhua Mi, Wei Qin
BACKGROUND: Immunoglobin A nephropathy (IgAN), the most prevalent form of primary glomerulonephritis, represents the leading cause of kidney failure among East Asian populations. Immunosuppressive treatment regimen, except for a 6-month trial of corticosteroids, has not been approved by the KDIGO guideline yet. Specific and effective treatment is still lacking. We decided to evaluate the efficacy and safety of the calcineurin inhibitors (CNIs) in the treatment of IgAN. METHODS: Database from the Cochrane library, PubMed, Embase, CBM, CNKI, and CENTRAL databases were searched and reviewed up to March 2016...
August 2016: Medicine (Baltimore)
Cristina Sarcina, Carmine Tinelli, Francesca Ferrario, Bianca Visciano, Antonello Pani, Annalisa De Silvestri, Ilaria De Simone, Lucia Del Vecchio, Veronica Terraneo, Silvia Furiani, Gaia Santagostino, Enzo Corghi, Claudio Pozzi
The clinical course of IgA nephropathy (IgAN) and its outcome are extremely variable. Proteinuria at baseline has been considered one of the most important risk factors. More recently, mean proteinuria of follow-up (time-average proteinuria: TAp) was described as a stronger marker of renal survival, suggesting to consider it as a marker of disease activity and response to treatment. We evaluated predictors of renal survival in IgAN patients with different degrees of renal dysfunction and histological lesions, focusing on the role of the therapy in influencing TAp...
2016: PloS One
Jun-Hua Liang, Yu-Wei Fang, An-Hung Yang, Ming Hsien Tsai
Methicillin-resistant Staphylococcus aureus (MRSA) is an emerging pathogen that infects the skin and soft tissue. However, there are few reports of renal complications from MRSA involving immunoglobulin (Ig)A-dominated rapidly progressive glomerulonephritis (GN). Favorable renal outcomes from IgA GN are achieved by administering timely therapy. In the present study, we describe the case of a healthy young woman suffering from a cutaneous MRSA infection that initially presented with gross hematuria. Six months after eradicating the infection, severe impairment of renal function was noted because of intractable nausea and vomiting...
June 2016: Medicine (Baltimore)
Yukio Yuzawa, Ryohei Yamamoto, Kazuo Takahashi, Ritsuko Katafuchi, Makoto Tomita, Yoshihide Fujigaki, Hiroshi Kitamura, Masashi Goto, Takashi Yasuda, Mitsuhiro Sato, Maki Urushihara, Shuji Kondo, Shoji Kagami, Yoshinari Yasuda, Hiroyuki Komatsu, Miki Takahara, Yasuaki Harabuchi, Kenjiro Kimura, Seiichi Matsuo
No abstract text is available yet for this article.
August 2016: Clinical and Experimental Nephrology
John Feehally, Jonathan Barratt
No abstract text is available yet for this article.
August 2016: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
Koichi Kamei, Ryoko Harada, Riku Hamada, Tomoyuki Sakai, Yuko Hamasaki, Hiroshi Hataya, Shuichi Ito, Kenji Ishikura, Masataka Honda
BACKGROUND: Proteinuria is the most important risk factor for IgA nephropathy progression. The purpose of this study is to evaluate the long-term outcome and risk factors for poor prognosis in childhood IgA nephropathy. METHODS: Patients who were diagnosed with IgA nephropathy between 1972 and 1992 at the Tokyo Metropolitan Kiyose Children's Hospital were included. We analyzed risk factors for progression to end-stage kidney disease (ESKD) and chronic renal insufficiency (CRI) using Kaplan-Meier method and multivariate analyses of Cox proportional hazard model...
2016: PloS One
Jürgen Floege, Thomas Rauen, Frank Eitner
No abstract text is available yet for this article.
March 10, 2016: New England Journal of Medicine
Riccardo Magistroni, Vivette D D'Agati, Gerald B Appel, Krzysztof Kiryluk
Recent years have brought notable progress in the field of IgA nephropathy. Here, we highlight important new directions and latest developments, including successful discovery of several genetic susceptibility loci, formulation of the multihit pathogenesis model, introduction of the Oxford pathology scoring system, and formalization of the Kidney Disease Improving Global Outcomes (KDIGO) consensus treatment guidelines. We focus on the latest genetic findings that confirm a strong contribution of inherited factors and explain some of the geoethnic disparities in disease susceptibility...
November 2015: Kidney International
Yasar Caliskan, Yasemin Ozluk, Dilara Celik, Nida Oztop, Aysun Aksoy, Ayse Serra Ucar, Halil Yazici, Isin Kilicaslan, Mehmet Sukru Sever
BACKGROUND/AIMS: The aim of this study is to investigate the utility of clinical [age, gender, mean arterial pressure (MAP)] and laboratory parameters [eGFR, hemoglobin (Hgb), serum levels of creatinine, uric acid, albumin, proteinuria, hematuria] and also histopathological lesions (Oxford classification parameters, crescents, intensity and pattern of staining for C3, C1Q, IgA, IgG, IgM) as progression markers in patients with IgA Nephropathy (IgAN). METHODS: A total of 111 IgAN patients with a follow-up period >1 year or who reached kidney failure [GFR category G5 chronic kidney disease (CKD)] <1 year were investigated...
2016: Kidney & Blood Pressure Research
Thomas Rauen, Frank Eitner, Christina Fitzner, Claudia Sommerer, Martin Zeier, Britta Otte, Ulf Panzer, Harm Peters, Urs Benck, Peter R Mertens, Uwe Kuhlmann, Oliver Witzke, Oliver Gross, Volker Vielhauer, Johannes F E Mann, Ralf-Dieter Hilgers, Jürgen Floege
BACKGROUND: The outcomes of immunosuppressive therapy, when added to supportive care, in patients with IgA nephropathy are uncertain. METHODS: We conducted a multicenter, open-label, randomized, controlled trial with a two-group, parallel, group-sequential design. During a 6-month run-in phase, supportive care (in particular, blockade of the renin-angiotensin system) was adjusted on the basis of proteinuria. Patients who had persistent proteinuria with urinary protein excretion of at least 0...
December 3, 2015: New England Journal of Medicine
Sandro Feriozzi, Rosaria Polci
The IgA nephropathy (IgAN) is a very common glomerulonephritis and can result in end-stage renal disease. From a clinical point of view, IgAN is characterised by repeated events of macrohaematuria associated with infections of the upper airways. In IgAN, the IgA released by the tonsillar lymphatic tissue into blood circulation are defective in glycosylation. These aberrant IgA can reach the glomeruli and deposit into mesangium causing an inflammation with cellular proliferation. The treatment is not yet well defined: steroids and immunosuppressive drugs are suggested in cases with a progressive disease...
February 2016: Journal of Nephrology
Mohamed R Daha, Cees van Kooten
Immunoglobulin A nephropathy (IgAN) is characterized by the deposition of IgA in the mesangium of glomeruli. This mesangial IgA has been found to consist mainly of polymeric IgA1 which drives the activation of the mesangial cells and results in excessive production of several inflammatory mediators. The activation of mesangial cells is amplified by the ability of IgA to activate the complement system, originally thought to occur mainly via the alternative pathway of complement. However more recent studies indicate that lectin pathway involvement has a strong association with progression of renal disease...
February 2016: Journal of Nephrology
2015-11-16 17:16:53
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"